T cells have been found to play a pivotal role in the immune response against cancer. In fact, the adoptive transfer of T cells expressing genetically engineered chimeric antigen receptors (CARs)¹ has shown great promise in clinical studies addressing chronic or acute lymphocytic leukemia²-³. However, the preparation of CAR T cells for clinical application is quite complex and comprises numerous handling steps.
1. Chmielewski, M. et al. (2013) Front Immunol. 4: 371
2. Kalos, M. et al. (2011) Sci. Transl. Med. 3: 95ra73.
3. Maus, M. V. et al. (2014) Blood 123: 2625–2635.